SIGA Technologies base_Aktie

SIGA Technologies base_Aktien 2025

SIGA Technologies base_Aktien

71,91 number_format_mio

components_StockPageHeader__3

SIGA

components_StockPageHeader__4

US8269171067

components_StockPageHeader__5

919473

pages_kennzahlen_[key]_[isin]__25

pages_kennzahlen_[key]_[isin]__70

components_DataTable__24components_DataTable__11
2026e71,91
2025e71,91
202471,91
202371,68
202273,50
202176,40
202079,40
201981,00
201882,70
201778,90
201657,20
201553,80
201453,40
201352,40
201251,60
201154,10
201045,20
200937,50
200834,70
200733,30
200628,20
200524,80

components_charts_SharesOutstandingChart_0

components_charts_SharesOutstandingChart_9
  • chart_toolbar_3y

  • chart_toolbar_5y

  • chart_toolbar_10y

  • components_charts_BaseChart_0

  • chart_toolbar_max

components_charts_SharesOutstandingChart_8
components_charts_RevenuePerShareChart_16

SIGA Technologies Aktienanalyse

pages_kennzahlen_[key]_[isin]__1

SIGA Technologies Inc was founded in 1995 and is headquartered in New York, USA. The company specializes in developing, producing, and distributing medical solutions for viral diseases, particularly for the treatment of smallpox. SIGA Technologies' business model is based on the development of antiviral drugs and vaccines that help in the treatment and prevention of infectious diseases. The company has a wide range of technologies and knowledge to develop innovative products. The focus is on researching viral diseases to find new treatment options and make them accessible. The company has several divisions that focus on different areas of virus infection treatment. The first division focuses on the treatment of smallpox. The company has produced the first approved medication for smallpox, Tecovirimat. Tecovirimat is an antiviral drug used for the treatment of smallpox. It is the only medication approved by the US Food and Drug Administration (FDA) for the treatment of smallpox. Another division of SIGA Technologies is dedicated to the development of antiviral agents that can control the spread of diseases such as Ebola, Lassa fever, and other viral diseases. The company has several promising drugs in the pipeline to meet the global demand for antiviral medications. SIGA Technologies also has innovative products in the diagnostics division. The company has developed a platform technology that allows for rapid and accurate diagnosis of virus infections. The platform, called AmpliPhi is Thermal Unwinding (AITU) technology, enables the diagnosis of a variety of virus infections and allows for targeted treatment to be initiated quickly. These tests can be performed both in laboratories and on-site, making them particularly valuable for use in medical facilities in rural areas or highly affected areas. Overall, SIGA Technologies has a broad portfolio of products and solutions for the treatment and prevention of virus infections. The company has an experienced and knowledgeable team of scientists and experts in this field, continuously driving new developments. SIGA Technologies is committed to making a contribution to improving global health and to having positive impacts on public health through its products and services. SIGA Technologies ist eines der beliebtesten Unternehmen auf Eulerpool.com.

pages_kennzahlen_[key]_[isin]__85

pages_kennzahlen_[key]_[isin]__76

pages_dividenden_[isin]_index__2

components_kpi_AktienFaqs_0

components_kpi_AktienFaqs_1

components_kpi_AktienFaqs_2

components_kpi_AktienFaqs_3

components_kpi_AktienFaqs_4

components_kpi_AktienFaqs_5

components_kpi_AktienFaqs_6

components_kpi_AktienFaqs_7

components_kpi_AktienFaqs_8

components_kpi_AktienFaqs_9

components_kpi_AktienFaqs_10

components_kpi_AktienFaqs_11

pages_aktie_[isin]_[key]_index_0

pages_aktie_[isin]_[key]_index_1

pages_aktie_[isin]_[key]_index_2

pages_aktie_[isin]_[key]_index_3

pages_aktie_[isin]_[key]_index_4

pages_aktie_[isin]_[key]_index_5

pages_aktie_[isin]_[key]_index_6

pages_aktie_[isin]_[key]_index_7

pages_aktie_[isin]_[key]_index_8

pages_aktie_[isin]_[key]_index_9

pages_aktie_[isin]_[key]_index_10

pages_aktie_[isin]_[key]_index_14

Wann musste ich die Aktien von SIGA Technologies kaufen, um die vorherige Dividende zu erhalten?

pages_aktie_[isin]_[key]_index_15

pages_aktie_[isin]_[key]_index_16

pages_aktie_[isin]_[key]_index_18

pages_aktie_[isin]_[key]_index_19

pages_aktie_[isin]_[key]_index_20

pages_aktie_[isin]_[key]_index_21

pages_aktie_[isin]_[key]_index_22

components_kpi_Savingsplan_0